Clinical Trial

Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 9, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy of Toripalimab combined with Chidamide in the treatment of relapsed/refractory peripheral T-cell lymphoma.
Protocol Amendment History 1 change
critical Trial status changed: Active, Not Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06492629
Lead Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions PTCL
Enrollment 43 participants
Start Date 2024-04-03
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-09